AACP
CDNA icon

Advantage Alpha Capital Partners’s CareDx CDNA Stock Holding History

Advantage Alpha Capital Partners’s Portfolio CDNA Stock Details CDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21,164
Closed -$308K – 25
2025
Q3 		$308K Buy
+21,164
New +$302K 0.09% 117

Other funds holding CDNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Advantage Alpha Capital Partners's CDNA Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of CareDx (CDNA) in Q4 2025, closing a stake of 21,164 shares — an estimated $308K sold.

Advantage Alpha Capital Partners first reported a position in CDNA in Q3 2025 and held it in 1 quarter. The position peaked at $308K in Q3 2025. 200 funds tracked by Wall St. Rank hold CDNA as of Q4 2025.

  • Advantage Alpha Capital Partners reported no remaining CareDx position as of Q4 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 21,164 CareDx shares in Q4 2025, an estimated $308K.
  • Advantage Alpha Capital Partners first reported a position in CareDx in Q3 2025 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's CareDx position peaked at $308K in Q3 2025.
  • 200 funds tracked by Wall St. Rank held CareDx as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.